Celularity Q2 10-Q: Going Concern Reaffirmed, $0.6M Cash, Nasdaq Filing Deficiency
CELU has more than doubled off its 52-week low of $0.56.
Summary
Celularity's Q2 2026 10-Q reaffirms substantial going-concern doubt with just $0.6M of cash, a $53.3M working capital deficit and a 46% revenue decline, while reported profit came from one-time NOL-sale and settlement gains. It also discloses a new Nasdaq filing delinquency and a default notice on the June 2026 Barach note.
Key Events · Earnings and Guidance · CELU
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the ability to continue as a going concern within one year; cash was $0.6M at June 30, 2026 versus $6.2M at December 31, 2025, with a $53.3M working capital deficit and $989.9M accumulated deficit.
-
Profit Is One-Time Gains
Six-month net income of $1.6M was driven by a $12.2M gain on selling New Jersey NOL carryforwards and a $6.7M gain on the Sequence settlement, partly offset by a $2.5M loss on the Helena settlement; operating cash flow of $0.3M was positive only because of the NOL proceeds.
-
Revenue Down 46%
Six-month revenue fell to $9.3M from $17.2M a year earlier, with product sales down 56.8% to $4.9M after the biomaterials out-license to NexGel; Q2 revenue was $5.4M versus $5.7M.
-
Nasdaq Filing Deficiency
An August 21, 2026 notice flags non-compliance with Nasdaq Rule 5250(c)(1) for the late Q2 10-Q; any extension runs no later than November 16, 2026, and delisting would severely impair liquidity and capital access.
Analysis · CELU · Life Sciences
The going-concern warning remains front and center in Celularity's delayed Q2 2026 10-Q: cash fell to $0.6M at June 30 from $6.2M at year-end, the working capital deficit is $53.3M, and the accumulated deficit stands at $989.9M. Reported six-month net income of $1.6M is not operating profit — it leans on a $12.2M gain from selling New Jersey NOL carryforwards and a $6.7M gain on the Sequence settlement, partly offset by a $2.5M loss on the Helena settlement. Revenue fell 45.9% to $9.3M as the biomaterials business was out-licensed to NexGel. Management also reaffirmed six material weaknesses in internal controls and disclosed a fresh Nasdaq timely-filing deficiency, with any extension capped at November 16, 2026. The September recapitalization ($9.7M gross, $8.8M net of an up-to-$25M program) is the only near-term funding cushion, and the June 2026 Barach note is already in default at 18% interest.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 44.5% of the 283 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.9M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.